Samsung Biologics buys Swiss peptide maker for $1.8bn

Samsung Biologics has acquired Swiss peptide manufacturer PolyPeptide for $1.8 billion, marking another step in South Korean firms' strategy of global expansion through strategic acquisitions. This move highlights Samsung Biologics' commitment to bolstering its biopharmaceutical production capabilities and enhancing its global footprint. The acquisition is particularly significant as peptides play a crucial role in the development of innovative drugs, signaling Samsung Biologics' ambition to stay at the forefront of advanced biologics manufacturing.